Chiome Bioscience (TSE:4583) Total Inventories : 円52.4 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Total Inventories?

Chiome Bioscience's total inventories for the quarter that ended in Jun. 2024 was 円52.4 Mil. Chiome Bioscience's average total inventories from the quarter that ended in Mar. 2024 to the quarter that ended in Jun. 2024 was 円55.7 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Chiome Bioscience's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was 円12.08.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chiome Bioscience's Days Inventory for the three months ended in Jun. 2024 was 90.28.

Inventory Turnover measures how fast the company turns over its inventory within a year. Chiome Bioscience's Inventory Turnover for the quarter that ended in Jun. 2024 was 1.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chiome Bioscience's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.42.

Chiome Bioscience Total Inventories Historical Data

The historical data trend for Chiome Bioscience's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Total Inventories Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

66.63

89.26

59.05

71.48

64.11

Chiome Bioscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Inventories	Get a 7-Day Free Trial															59.74	58.09	64.11	59.01	52.44

Chiome Bioscience Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Chiome Bioscience (TSE:4583) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Chiome Bioscience's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

	Net-Net Working Capital Per Share (Q: Jun. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1103.656	+	0.75 * 50.693	+	0.5 * 52.443	-	486.908
-	0	-	0)	/	56.3809
=	12.08

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chiome Bioscience's Days Inventory for the three months ended in Jun. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2024 )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
	=	55.724	/	56.324	*	365 / 4
	=	90.28

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Chiome Bioscience's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2024 )	/	Average Total Inventories (Q: Jun. 2024 )
	=	56.324	/	55.724
	=	1.01

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chiome Bioscience's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	55.724	/	134.084
	=	0.42

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Chiome Bioscience Total Inventories Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines